Endoscopic and Histological Placebo Rates in Crohn’s Disease Clinical Trials: A Systematic Review and Meta-analysis
Sudheer K. Vuyyuru(All India Institute of Medical Sciences), Vipul Jairath(McMaster University), Bram Verstockt(Universitair Ziekenhuis Leuven), Neeraj Narula(McMaster University), Nurulamin M Noor(Cambridge School), Christopher Ma(University of Calgary), Brian G. Feagan(Western University), Tim Raine(National Health Service), Malcolm Hogan, Tran M Nguyen(Western University), Siddharth Singh(Mayo Clinic in Arizona)
Cited by 8
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k